Health Condition 1: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung
Conditions
Interventions
Intervention1: NIL: NIL
Control Intervention1: NIL: NIL
Sponsors
Tata Memorial Centre
Eligibility
Inclusion criteria
Inclusion criteria: 1. The availability of sufficient archival tumor tissue specimen 2. Age >= 21 years 3. WHO performance status ï?£ 2 4. Life expectancy of >= 12 weeks 5. Patients should have adequate organ function for potential consideration into clinical trials (routine blood tests are valid within 14 days before enrollment): o Adequate bone marrow function as shown by: ANC >= 1.0 x 109/L, Platelets >= 75 x 109/L, Hb >= 7.5 g/dL o Alanine aminotransferase (ALT) and aspirate aminotransferase (AST) normal range (or 6. Willing to provide signed informed consent 7. Patients whom do not fulfill the above criteria may be discussed on a case-by-case basis with the study team, for potential enrolment
Exclusion criteria
Exclusion criteria: 1. No more than 3 lines of cytotoxic chemotherapy at the time of enrolment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.To evaluate the molecular epidemiology of NSCLC in Asia via comprehensive, prospective molecular profiling of lung cancer specimens â?? in both resected tumours and small biopsy specimens. 2.To develop a predictive model based on clinical-pathologic characteristics in Asian NSCLC patients. Timepoint: 1.Baseline 2. 2 years | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.To ascertain the extent of access to novel/targeted therapies and immunotherapy for patients found to have an actionable biomarker. 2. To determine outcomes of patients (PFS and OS) in molecularly defined subgroups of NSCLC. Timepoint: 1. 2 years 2. Till disease Progression and / or till death | — |
Countries
India, Singapore
Contacts
Public ContactDr Nandini Menon
Tata Memorial Centre
Outcome results
None listed